Product Description
Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully qualified, fraud-free Lemtrada stroke and arterial dissection injury cases. Here at Leading Justice, we can customize your firm’s Lemtrada advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Lemtrada injury advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that doesn’t qualify for the target campaign is evaluated to determine whether it qualifies for another type of claim. By using innovative approaches to target contacts specifically related to Lemtrada and side effects like stroke, head or neck arterial dissection and wrongful death, Leading Justice will increase your firm’s Lemtrada injury caseload. If you are interested in helping victims of Lemtrada side effects, our direct advertising strategies and extensive consumer reach at Leading Justice gives you the competitive edge and confidence you need to allocate your full budget, with the knowledge that your money is being spent in the best way possible.
Each law firm we work with at Leading Justice plays a critical role in determining how we classify claims as qualified or not. Our experience working with plaintiff law firms helps us to recognize a great case when we see one, but we will customize our Lemtrada injury intake specifications to the exact criteria you are seeking. So, if your firm has specific Lemtrada qualifying case criteria you want us to use, we can train our intake specialists to apply the criteria to each email and phone call they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of Lemtrada injury data with no chance of fraud.
Lemtrada Stroke and Arterial Dissection Injury Litigation
Lemtrada, known generically as alemtuzumab, is a disease-modifying treatment prescribed to patients with relapsing forms of multiple sclerosis (MS) who have already been treated with two or more other drugs with an inadequate response. Multiple sclerosis is an autoimmune disease in which the immune system eats away at the protective covering of the nerves in the brain and spinal cord, resulting in a number of debilitating neurological symptoms, such as pain, vision loss and impaired coordination. More than two million people worldwide suffer from MS and there is no cure for the disease, but Lemtrada has been shown to slow down the progression of MS and reduce the occurrence of MS relapses. Lemtrada was approved by the U.S. Food and Drug Administration (FDA) in 2014 and is administered as an intravenous infusion in two separate treatment courses, one year apart.
Since Lemtrada first entered the market, more than 21,000 MS patients have been treated with the disease-modifying therapy worldwide, after Lemtrada clinical trial results demonstrated the drug’s potential to reduce relapse rates in patients with relapsing-remitting MS. In November 2018, however, just four years after Lemtrada was initially approved in the United States, the FDA issued a drug safety communication warning about “rare but serious cases of stroke and tears in the lining of arteries in the head and neck” occurring in MS patients treated with Lemtrada, indicating that “These problems can lead to permanent disability and even death.” Of the 13 worldwide cases of ischemic and hemorrhagic stroke or arterial dissection identified by the FDA in connection with Lemtrada treatment, 12 patients reported experiencing side effects within just one day of beginning the infusion therapy. As concerns about the safety of Lemtrada for MS continue to grow, lawyers across the country are investigating claims on behalf of MS patients who suffered serious or fatal strokes or arterial dissections occurring in the head or neck after receiving Lemtrada treatment.
